Prograf
Manufacturing · Illinois, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
873 E Equestrian Pointe Dr, Oregon, Illi...Phone Number
(815) 234-4848Website
www.prograf.comRevenue
$21.5 MillionIndustry
About Prograf
Astellas Pharma US, Inc. offers PROGRAF, a prescription medication designed to prevent organ rejection in patients who have undergone kidney, liver, heart, or lung transplants. The product is available in capsule and granule forms, specifically formulated as immediate-release tacrolimus drugs. Astellas also provides educational support through Astellas Cares, assisting patients and healthcare providers in managing post-transplant care. The company focuses on delivering effective solutions for transplant patients while ensuring safety and proper medication management.Explore more
Prograf Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Prograf
Compare insights from companies similar to Prograf, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Prograf Tech Stack
A closer look at the technologies used by Prograf
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Prograf
Sign Up For FreeTo access detailed company insights
Astellas Pharma US, Inc. offers PROGRAF, a prescription medication designed to prevent organ rejection in patients who have undergone kidney, liver, heart, or lung transplants. The product is available in capsule and granule forms, specifically formulated as immediate-release tacrolimus drugs. Astellas also provides educational support through Aste... Read More
